What's going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares edge 1.54% higher to $1.32 after reaching an intraday high of $1.41 in morning trade 
  • Polynovo chair David Williams again took advantage of the recent share price weakness, buying $231,000 worth of Polynovo shares 
  • The company's share price touched a 52-week low of 83.5 cents earlier this month 

The Polynovo Ltd (ASX: PNV) share price rocketed as high as 8.65% during market open but has since fallen wayside.

At the time of writing, the medical device company's shares are swapping hands at $1.32, up 1.54%.

This follows the All Ordinaries Index's (ASX: XAO) lead which rose to an intraday high within the first hour of trade.

However, since then, the broader ASX index has given back its gains to fetch at 7, 328 points, up 0.28%.

Director tops up on Polynovo shares

An insider has again recently taken advantage of the Polynovo share price weakness to top up their holdings.

In its most recent statement, Polynovo revealed that its chair, David Williams picked up more shares.

In total, 181,532 Polynovo shares were bought through his subsidiary, Lawn Views Pty Ltd via an on-market trade.

The indirect acquisition occurred on 13 May, and the average price paid per Polynovo share was $1.2746.

This means that Mr Williams now has around 21.50 million fully paid ordinary Polynovo shares across all his holdings.

The above transaction equated to the value of more than $231,000.

It is worth nothing that in the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents. Since then, a number of directors, particularly Mr Williams have made a series of purchases.

Polynovo share price snapshot

It appears that the latest purchases could be spooking short sellers to close on their positions. ASIC is due to release its short position report mid-week, which will indicate where Polynovo shares are at.

On 9 May, the company had a reported short interest of 10.54%. This puts Polynovo as one of the most shorted shares on the ASX.

Despite this month's gains, Polynovo shares have fallen by around 50% over the past 12 months.

Based on today's price, Polynovo commands a market capitalisation of roughly $860.19 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Key Canadian approval sends 10-bagger biotech's shares higher

This 10-bagger company has just released more good news, with a breakthrough in the Canadian market.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This biotech has lodged a key submission with US regulators

This company has lodged a key submission which will pave the way for sales of its heart failure software in…

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Let’s look at what experts are expecting from the healthcare giant in 2026.

Read more »

medical doctor performing surgery using surgical instruments
Healthcare Shares

Biotech company implants heart device in world first

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets.

Read more »